Table 3 |
|||
|
Toxicities by grade and causality in the newly diagnosed GBM patients treated with combined TTFields-Temozolomide. |
|||
|
Grade |
Causality assessment |
||
|
|
|||
|
I-II |
III-IV |
||
|
|
|||
|
Elevated LFTs |
6/10 |
0/10 |
Anti Epileptic Drugs |
|
Hyperglycemia |
4/10 |
0/10 |
Oral Steroids |
|
Anemia |
6/10 |
0/10 |
Temozolomide |
|
Thrombocytopenia |
2/10 |
0/10 |
Temozolomide |
|
Leucopenia |
3/10 |
0/10 |
Temozolomide |
|
Headache |
2/10 |
0/10 |
Underlying disease |
|
Seizures |
1/10 |
0/10 |
Underlying disease |
|
Dermatitis |
10/10 |
0/10 |
NovoTTF-100A |
|
|
|||
|
Kirson et al. BMC Medical Physics 2009 9:1 doi:10.1186/1756-6649-9-1 |
|||
